Skip to main content
Loading market data...

REVS holdings

Columbia Research Enhanced Value ETF

Source: SEC Form N-PORT (opens in a new tab) Holdings as of Made public 28 Sep 2026

Positions

307 stored of 307 reported, largest first by weight

REVS holdings as of 31 Jul 2026, largest first
# Holding ISIN CUSIP Weight Value (USD) Type Issuer type Country Currency
301 Bridgebio Pharma Inc US10806X1028 10806X102 0.002% $7K Equity (common) Corporate United States USD
302 CONTRA WALGREENS BOOTS US931CVR0133 931CVR013 0.002% $6K Equity derivatives Other United States USD
303 Ascendis Pharma A/S DK0060615755 Not reported 0.002% $6K Equity (common) Corporate Denmark USD
304 Ionis Pharmaceuticals Inc US4622221004 462222100 0.001% $4K Equity (common) Corporate United States USD
305 Caris Life Sciences Inc US1421521071 142152107 <0.001% $2K Equity (common) Corporate United States USD
306 CONTRA HOLOGIC INCORPO US436CVR0216 436CVR021 <0.001% $92 Equity derivatives Other United States USD
307 CONTRA MIRATI THERAPEU Not reported 604CVR027 <0.001% $26 Equity derivatives Other United States USD
IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.

Catalyst evidence

Loading…

Loading evidence…

Supporting sources

    Skip to main content

    All resources and tools

    Market ticker

    Markets

    Research

    Tools

    My investments

    Account

    Region and currency

    Colour theme